HCA Healthcare’s first quarter results in 2026 were met with a negative market reaction, despite matching Wall Street’s revenue and profit expectations. Management highlighted that the primary drivers behind the results were a significantly milder respiratory season and the impact of a severe winter storm, both of which depressed patient volumes, especially in admissions and emergency room visits. CEO Samuel Hazen noted, “Compared to the first quarter of last year, our respiratory-related admissions were down 42%.” These volume shortfalls, however, were mostly offset by higher-than-expected benefits from state Medicaid supplemental programs and ongoing cost efficiencies. Management acknowledged the challenging operating environment, especially as payer mix shifts and state program uncertainties introduced variability in performance.
Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).
HCA Healthcare (HCA) Q1 CY2026 Highlights:
- Revenue: $19.11 billion vs analyst estimates of $19.08 billion (4.3% year-on-year growth, in line)
- Adjusted EPS: $7.15 vs analyst expectations of $7.13 (in line)
- Adjusted EBITDA: $3.80 billion vs analyst estimates of $3.85 billion (19.9% margin, 1.4% miss)
- Operating Margin: 15%, in line with the same quarter last year
- Market Capitalization: $96.66 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From HCA Healthcare’s Q1 Earnings Call
- Ben Hendrix (RBC Capital Markets) asked for clarification on the main drivers behind the quarter’s EBITDA shortfall. CFO Mike Marks explained that the key factors were lower seasonal volume and winter storm impacts, mostly offset by higher Medicaid supplemental benefits.
- Ann Hynes (Mizuho Securities) inquired about the timing of the Florida Medicaid supplemental program approval and the impact of rising uninsured and bad debt. Marks said they are optimistic about Florida’s approval but cautioned that patient collections from exchanges remain challenging.
- Whit Mayo (Leerink Partners) pressed on changes in payer behavior, especially regarding denials and underpayments. Marks described increased denial activity industry-wide but said HCA’s investments in revenue cycle management and digital integration are helping mitigate earnings impact.
- Benjamin Rossi (JPMorgan) asked about the pace of network expansion and the role of acquisitions. CEO Hazen noted a strong pipeline of approved projects and continued focus on outpatient acquisitions to complement hospital operations.
- Matthew Gillmor (KeyBanc) questioned whether the company had adjusted its bad debt accrual process in response to rising uninsured volumes. Marks responded that the company’s 2026 plan anticipated these shifts and that recent trends are within modeled expectations.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be closely watching (1) approval and timing of the Florida Medicaid supplemental program, which could materially affect revenue, (2) continued execution and measurable results from HCA’s $400 million resiliency and AI-driven cost savings initiatives, and (3) stabilization of payer mix and uninsured trends as the health insurance exchange environment remains unsettled. Progress on network expansion projects and outpatient acquisitions will also be key indicators of sustainable growth.
HCA Healthcare currently trades at $433.38, down from $474.03 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
